PDE4A and early-onset autosomal dominant Alzheimer disease: Although much has been learned about the potential benefits of PDE4 inhibitors in the treatment of aging-related diseases such as Alzheimer's disease [7,8,19], relatively little is known about their effects on adipose deposition and metabolic disorders during aging.